Sentences with phrase «of tumor profiles»

One project involves probing Foundation Medicine's growing database of tumor profiles for specific mutations and using that information to either design drugs or to parse patients into clinical trials of the company's drugs, says Pao.

Published online by JCI Insight, it is the first report of «clinical implementation of tumor profiling in an enterprise - wide, unselected cancer patient population,» according to the authors.

Our experts leveraged enormous amounts of tumor profiling data to identify the validated therapies that are most likely to be effective against this subtype of NSCLC.

Not exact matches

As researchers learn more about genetic profile of various cancers, other work is charging ahead to deliver personalized vaccines targeted to a patient's own tumor cells

«Next generation sequencing tools were used to profile patients» tumors,» said Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at UC San Diego Moores Cancer Center.

Traditional genetic approaches together with the new wealth of genomic information for both human and model organisms open up strategies by which drugs can be profiled for their ability to selectively kill cells in a molecular context that matches those found in tumors.

Then they linked the drug sensitivity of the tumor cells to the profile of genes expressed in those cells.

In a recent attempt, oncologist Todd Golub of the Dana - Farber Cancer Institute in Boston, Massachusetts, and his colleagues collected gene expression profiles, taken from public databases, from 76 tumors.

In a scenario where tumor profiling was already ordered, 79 % of patients stated they wanted to know all of the information obtained.

The 15 AACR scientists, who were already in Washington, D.C., to meet with the U.S. Food and Drug Administration on genetic testing for cancer patients, tossed around ideas including expanding NCI's tumor genome - sequencing efforts and getting the government to cover the costs of genomic tumor profiling.

The study showed that despite the risk for receiving information about other potentially serious health problems, 59 % of the cancer patients would agree to tumor profiling if offered by their physician.

«While tumor profiling holds the promise of improved therapeutics through personalized medicine, it is important that both clinicians and patients discuss the possibilities of incidental findings prior to ordering the testing, as the findings can have serious implications for both the patient and their family members,» said Melinda Yushak, M.D., M.P.H., first author on the study and a medical oncology fellow in Yale School of Medicine.

A new effort by DOD, NCI, and the Department of Veterans Affairs will profile gene and protein expression in thousands of individuals» tumors.

Caris performed the molecular profiling on 48,733 solid tumor samples to assess the prevalence of homologous recombination deficiency in about 20 different types of solid tumors.

Researchers from BUSM and the University of Cyprus compared the markers on the surface of the cancer cells to gene expression profile of breast tumors deposited by researchers in international public databases and found that a molecule named IL13RA2 (IL13R alpha2) was abundant in metastatic or late - stage BLBC.

Nagrath, director of Rice's Laboratory for Systems Biology of Human Diseases, said the new metabolic analysis indicates that ovarian cancer may be susceptible to multidrug cocktails, particularly if the amounts of the drugs can be tailored to match the metabolic profile of a patient's tumor.

The study also suggests how ovarian cancer treatments can be tailored based on the metabolic profile of a particular tumor.

Researchers at Rice University's Laboratory for Systems Biology of Human Diseases analyzed the metabolic profiles of hundreds of ovarian tumors and discovered a new test to determine whether ovarian cancer cells have the potential to metastasize.

«We found a striking difference between the metabolic profiles of poorly aggressive and highly aggressive ovarian tumor cells, particularly with respect to their production and use of the amino acid glutamine,» said lead researcher Deepak Nagrath of Rice.

The resulting «map» of gene - drug interactions allowed the researchers to accurately predict the responses of multiple human cancer cell lines to different chemotherapy agents based on the cell lines» genetic profiles and also revealed new genetic factors that appear to determine the response of breast and ovarian tumor cells to common classes of chemotherapy treatment.

The study — Genomic profiles of low - grade murine gliomas evolve during progression to glioblastoma — published April 7, shows how these tumors continue to rapidly evolve, becoming ever more genetically diverse, as they become malignant and progress.

In 2011, she joined the institution's molecular diagnostics laboratory where she has been developing translational next generation sequencing assays and bioinformatics workflows for the Molecular Tumor Profiling Lab of the Yale Cancer Center.

This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular profile of individual tumors and the genetic background of patients.

Researchers developed models to examine the influence of driver mutations — mutations that promote cancer development — on the initiation and development of gliomas, and how tumor genomic profiles evolve as the cancer progresses.

«These findings raise the possibility that by determining the gene expression profile of a patient's tumor, physicians may be able to identify aggressive disease at the outset of diagnosis and start treatment earlier,» said Sungyong You, PhD, an instructor in the Cedars - Sinai Department of Surgery and the first author of the study.

«The idea is that every patient will receive a unique cocktail of neoepitope - derived peptides, based on the genetic profile of a tumor, to generate a highly immunogenic and clinically relevant response,» he says.

The investigators also identified instances in which the genetic profiles of metastases were similar to those of only some cells in the primary tumor, suggesting that those cells were the source of the metastases, and other cases in which the genetic profiles of metastases from the same primary differed depending on their location.

Analyzing the poly - G profiles of primary and metastatic colon cancer samples from 22 patients revealed that how the primary and metastatic tumors related to each other was different for each patient.

A team led by principal investigator Donald M. O'Rourke, MD, an associate professor of Neurosurgery at Penn, and Marcela Maus, MD, PhD, showed that CART - EGFRvIII cells had an acceptable safety profile, crossed the blood - brain barrier, infiltrated the tumor, and prompted an immune response, resulting in reduction of the EGFRvIII tumor antigen in GBM cells.

The total environmental DNA of grape crown gall tumor disease is revealed in the genetic profile based on 52 tissue samples of crown gall tumor taken from 16 grapevine species.

Previously, genetic counselors tested a small number of genes sequentially based on family profile and tumor analysis until the culprit was identified.

Research from Rutgers Cancer Institute of New Jersey examining difficult to treat cancer tumors through genomic profiling shows that tumors with alterations in a signaling pathway responsible for cell regulation may respond to targeted therapy regardless of where the tumor originated in the body.

Just over half of patients in the study who gave consent and had tumor profiling ordered by a physician actually received results, due to a variety of technical and logistical factors.

There's a basic set of mutational profiling that's done all around the country but there are certain centers, including ours, that have access to a much wider set of genetic profiling of the tumors.

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors» mutations or being enrolled in clinical trials.

Tumor profiling can also reveal rare mutations and other changes that make some cancers unusually responsive to targeted drugs — knowledge that can be applied to patients with a variety of cancer types.

The study wasn't designed to measure whether tumor profiling made a difference in how patients fared, but «it nonetheless lays the groundwork for more systematic study of the impact of genomics on clinical practice and patient outcomes,» the report said.

Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor.

Individual profiles based on the analysis of each patient's tumor cells revealed clinically relevant information that could be used to prioritize the drugs most likely to be effective in these cases.

Many of our brain tumor clinical trials include analysis of the molecular profiles of patients» tumors.

In recent years DNA - and RNA - based surveys of tumor genome and expression profiling have produced a plethora of leads on genes with clinical significance.

A detailed comparison of gene expression signatures between ETP ALL tumors and and normal human hematopoietic progenitor cells revealed a somewhat surprising finding: ETP - ALL expression patterns were less consistent with early T - cell precursors, as might have been expected, but more similar to the expression profile of normal hematopoietic stem cells and granulocyte macrophage precursors.

Furthermore, the genetic and expression profiles of malignant cells vary within individual tumors, between tumors at different sites within the same patient, and among tumors from different patients.

The fact that she has found them to be differentially regulated in angiosarcoma tumors has led to the hypothesis that there are epigenetic regulators of these genes that have yet to be identified through the genomic profiling applied to these studies thus far.

In the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the genetic conditions predisposing to tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her genetic profile, in other words, the analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.»

To determine the relevance of DDX3 in clinical cancers, the expression profile of DDX3 in various tumors was also examined.

PHOTO: Harbour LaboratoryUsing very small amounts of tumor tissue collected by a needle biopsy, doctors can conduct gene expression profile testing to determine the likelihood that an ocular melanoma tumor will spread beyond the eye.

To further confirm the alteration of DDX3 expression in cancer specimens, the expression profiles of DDX3 were examined in normal - tumor paired HCC samples by immunohistochemical staining analysis using specific anti-DDX3 antibody.

A clinical trial of AI therapy response paired with next - gen sequencing offers the opportunity to profile the genetic alterations of AI - sensitive and AI - resistant tumors.

Using an array of techniques, including RNA sequencing and targeted gene expression profiling, the researchers searched for links between gene activity and protein production in these tumors and the clinical outcomes of patients.